A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs ACTR 087 (Primary) ; SEA-BCMA (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Unum Therapeutics
  • Most Recent Events

    • 28 Aug 2017 New trial record
    • 23 Aug 2017 According to an Unum Therapeutics media release, the IND application for the combination is now active. Site initiation activities are currently underway and the Company anticipates to initiate patient dosing in Q1 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top